Myroslava Kulyk

Myroslava Kulyk

Auto-generated profile, based on publicly available information

Myroslava Kulyk

KU Leuven Skeletal Biology and Engineering Research Center Leuven

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MKMyroslava Kulyk
Myroslava Kulyk
MDMarta Dzhus
Marta Dzhus
Sarcopenia is a disease characterized by decreasing muscle mass and strength or performance. The prevalence of sarcopenia in rheumatic diseases has been evaluated in single diseases using various diagnostic approaches, generating conflicting data. The study aims to investigate sarcopenia prevalence in young adults with inflammatory arthritis (IA) and to detect factors associated with low muscle mass and strength. The single-center, cross-sectional study included 138 young adults with IA. Dynamometry with a Jamar hand dynamometer was used to determine handgrip strength. Thresholds for reduced muscle strength were < 27 kg for males and < 16 kg for females. To determine skeletal mass index (SMI), dual photon X-ray absorptiometry (DXA) was done with such cut-off points < 5.67 kg/m2 in females and < 7.0 kg/m2 in males. Patients with both reduced muscle mass and strength were considered as sarcopenic. Logistic regression analyses estimated between sarcopenia and associated factors. Statistical significance was defined as a p-value < 0.05. The prevalence of sarcopenia was about 47% in all IA and was significantly different between juvenile idiopathic arthritis (JIA), spondyloarthritis (SpA), and rheumatoid arthritis (RA) groups (p = 0.006). At multivariable analysis, body mass index (BMI) (OR 0.84; CI 95% 0.72–0.86, p = 0.02), bone mineral density (BMD) at femur neck (OR 0.01; CI 95% 0.001–0.268, p = 0.01), 25-hydroxyvitamin D (25(OH)D) (OR 0.96; CI 95% 0.93–0.98, p = 0.001), and disability by Health Assessment Questionnaire (HAQ) (OR 14.54; CI 95% 4.92–51.77, p < 0.001) were associated with a significantly increased risk of sarcopenia. The results of our study demonstrate a high prevalence of sarcopenia among young patients with IA. In these participants, lower BMI, lower BMD, 25(OH)D concentration, and higher HAQ were linked to sarcopenia.

30 June 2020 in Annals of Geriatric Medicine and Research
Verified
Journal Article
Open access
PDF file
MDMarta Dzhus
Marta Dzhus
MDMaria Dzhus
Maria Dzhus
MMMarta Masnyi
Marta Masnyi
MKMyroslava Kulyk
Myroslava Kulyk
HMHalyna Mostbauer
Halyna Mostbauer
CBCharlotte Beaudart
Charlotte Beaudart
The SarQoL, a quality-of-life questionnaire specific to sarcopenia, was developed in 2015 and has since been translated into a number of other languages. The main reason to introduce this new Ukrainian version of the questionnaire was to measure sarcopenic individuals’ perceptions regarding their positions in life in the context of their culture and value systems. The questionnaire was translated using a forward-backward approach with a pre-test. A total of 49 participants were recruited for the validation study. Sarcopenia was diagnosed according to the Ishii test. The validation analyses included discriminative power, internal consistency, floor and ceiling effects, construct validity, and test-retest reliability. We compared the SarQoL questionnaire to the Short-Form 36 and the EuroQoL-5 Dimensions. A total of 28 participants out of 49 were categorized as probably sarcopenic. They had a significantly lower quality of life (overall score 58.43±17.13 vs. 69.89±13.31; p=0.014). The internal consistency was excellent (α=0.898), with none of the domains showing a disproportionate influence on the homogeneity of the questionnaire. Convergent construct validity was also confirmed. The results indicated a near-perfect degree of test-retest reliability. The first Ukrainian version of the questionnaire is equivalent to the available original English version.

7 August 2024 in RMD Open
Verified
Journal Article
Open access
PDF file
DBDelphine Bertrand
Delphine Bertrand
JJJohan Joly
Johan Joly
BNBarbara Neerinckx
Barbara Neerinckx
PDPatrick Durez
Patrick Durez
JLJan Lenaerts
Jan Lenaerts
PVPatrick Verschueren
Patrick Verschueren
Objectives To investigate if patients with early rheumatoid arthritis responding insufficiently to initial methotrexate (MTX) and bridging glucocorticoids (GCs) could benefit from early but temporary etanercept introduction as a second remission-induction attempt. Methods CareRA2020 (NCT03649061) was a 2-year, open-label, multicentre, pragmatic randomised controlled trial. Treatment-naïve patients started MTX and GC bridging (COBRA-Slim: CS). Within a time window from week (W) 8 until W32, early insufficient responders (28-joint Disease Activity Score – C-reactive Protein (DAS28-CRP) >3.2 between W8 and W32 or ≥2.6 at W32) were randomised to a Standard-CS strategy (adding leflunomide first) or Bio-induction-CS strategy (adding etanercept for 24 weeks). Additional treatment adaptations followed the treat-to-target principle. Longitudinal disease activity (DAS28-CRP) over 104 weeks (primary outcome), achievement of DAS28-CRP <2.6 28 weeks after randomisation, and biologic or targeted synthetic disease-modifying antirheumatic drug (b/tsDMARD) use at W104 were compared between randomisation groups. Results Following CS treatment, 142 patients were early responders; 55 early insufficient responders received Standard-CS and 55 Bio-induction-CS. Superiority of Bio-induction-CS over Standard-CS could not be demonstrated (ß=−0.204, (95% CI –0.486 to 0.078), p=0.157) for the primary outcome. More patients on Bio-induction-CS achieved DAS28-CRP <2.6 at 28 weeks after randomisation (59% (95% CI 44% to 72%) vs 44% (95% CI 31% to 59%) in Standard-CS) and they were treated less frequently with b/tsDMARDs at W104 (19/55, 35%) compared with Standard-CS (29/55, 53%). Conclusion Half of the patients responded well to initial COBRA-Slim induction therapy. In early insufficient responders, adding etanercept for 6 months did not improve disease control over 104 weeks versus adding leflunomide first. However, temporary introduction of etanercept resulted in improved disease control early after randomisation and less patients on b/tsDMARDs at W104. Trial registration number NCT03649061. CTR pilot approval Belgium S59474, EudraCT number: 2017-004054-41.

18 November 2024 in BMC Musculoskeletal Disorders
Verified
Journal Article
Open access
PDF file
MKMyroslava Kulyk
Myroslava Kulyk
MDMarta Dzhus
Marta Dzhus
Sarcopenia is a generalized loss of skeletal muscle mass, strength, and performance, and early identification is crucial to minimize adverse outcomes. While sarcopenia is well-studied in older populations, data on its prevalence and risk factors in young adults with juvenile idiopathic arthritis (JIA) remain limited. The study aimed to evaluate the prevalence of sarcopenia in young adults with JIA and to identify associated risk factors. A cross-sectional single-center study was conducted at the Rheumatology Department of Communal Noncommercial Institution “Oleksandrivska Clinical Hospital”, Kyiv, Ukraine, involving 70 patients between November 2020 and November 2022. Initially, 84 patients were recruited; however, 14 were excluded due to joint replacement, diabetes, or refusal to participate. Sarcopenia was diagnosed using the Find-Assess-Confirm-Severity algorithm, assessing muscle strength with a dynamometer, confirming sarcopenia using dual-energy X-ray absorptiometry, and determining severity via gait speed tests. Univariable and multivariable logistic regression was used to identify factors associated with sarcopenia and reported as odds ratios (OR) and 95% confidence intervals (95% CI). Low handgrip strength, sarcopenia, and severe sarcopenia were observed in 64% (45/70), 59% (41/70), and 34% (24/70) of the patients, respectively. Men were less likely to lose muscle mass than women were (OR 0.29, 95% CI 0.10–0.89; p = 0.03). Sarcopenia was significantly predicted by disease activity according to the Disease Activity Score 28 based on erythrocytes sedimentation rate (DAS28-ESR) and clinical Juvenile Arthritis Disease Activity Score (cJADAS27) (OR 2.08, 95% CI 1.15–3.76; p = 0.01; OR 1.15, 95% CI 1.04–1.27; p = 0.007, respectively), articular and extra-articular Juvenile Arthritis Damage Index (JADI) (JADI-A OR 2.29, 95% CI 1.23–4.25; p = 0.009; JADI-E OR 3.15, 95% CI 1.36–7.29; p = 0.008, respectively), and functional capacity according to the Health Assessment Questionnaire (OR 4.14, 95% CI 1.38–12.5; p = 0.01). Sarcopenia in young adults with JIA was associated with disease activity (measured by DAS28-ESR and cJADAS27), articular and extra-articular damage (measured by JADI indices), and lower functional capacity.

24 January 2026 in Pediatric Rheumatology
Verified
Journal Article
Open access
PDF file
MKMyroslava Kulyk
Myroslava Kulyk
OYOleksandr Yeremiya
Oleksandr Yeremiya
RWRene Westhovens
Rene Westhovens
KVKurt De Vlam
Kurt De Vlam
MDMarta Dzhus
Marta Dzhus
Muscle deficits are a recognized complication of juvenile idiopathic arthritis (JIA), but the long-term consequences of these alterations into adulthood ar

30 June 2023 in PAIN, JOINTS, SPINE
Verified
Journal Article
Open access
PDF file
MKM. Kulyk
M. Kulyk
MDMarta Dzhus
Marta Dzhus
Background. Handgrip strength (HGS) and physical activity (PA) reflect an individual’s overall health and can predict morbidity and mortality. The purpose of the study was to investigate the level of PA and HGS and associated factors in young adults with juvenile idiopathic arthritis (JIA) and determine the connection with body composition parameters. Materials and methods. We conducted a cross-sectional monocentric study of 40 young adults aged 18–30. We collected data on PA and anthropometric and clinical measurements, including disease activity and articular and extra-articular damages. All patients had the following evaluations performed: body composition (dual X-ray absorptiometry), PA level (International Physical Activity Questionnaire), and HGS measurement (using manual hand dynamometer). Results. Sixteen (40 %) patients were considered sedentary, and 32 (80 %) JIA patients had low HGS. The reduced HGS was likely in women, patients with lower body mass index, higher disease activity, and articular damage. In contrast, bone mineral density (BMD) and lean mass were protective factors for reduced HGS (p < 0.05). The level of PA was positively correlated with BMD and lean mass and negatively correlated with fat mass, swollen joint count, and articular damage (p < 0.05). Conclusions. JIA leads to changes in body composition parameters, particularly lean (muscle) mass and muscle strength, and therefore is a risk factor for the development of sarcopenia.